Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 9 (TRAJ9) is a short segment of DNA found on chromosome 14 that encodes the joining (J) region used in the assembly of the T cell receptor alpha (TRA) chain[4]. This region participates in somatic recombination, where it is joined with variable (V) gene segments (such as TRAV9-1 or TRAV9-2) and a constant (C) gene segment to generate the gene encoding the alpha chain of the T cell receptor[2][3][4]. TRAJ9 itself does not encode a standalone functional protein, enzyme, or receptor, but rather serves as a recombinatorial element in building T cell receptor diversity[3]. It is not considered a therapeutic target, and TRAJ9 mutations or characteristics are not directly associated with therapeutic strategies, biomarkers, or disease mechanisms. **Key point:** TRAJ9 is one of many joining segments essential for the diversity of the antigen-recognizing α-chain of the T cell receptor, but it is not itself a receptor, drug target, nor directly involved in disease roles or therapeutic mechanisms[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 9 (TRAJ9).